No Vacillation on HPV Vaccination
Publication date: 8 March 2018 Source:Cell, Volume 172, Issue 6 Author(s): Douglas Sipp, Ian H. Frazer, John E.J. Rasko Evidence of the safety and protective benefits of human papillomavirus virus (HPV) vaccines as an anti-cancer measure is overwhelming. However, vaccine uptake varies widely across countries and falls short of levels needed to achieve population immunity. We highlight policy measures that would help ensure greater worldwide coverage and save lives. Teaser Evidence of the safety and protective benefits of human papillomavirus virus (HPV) vaccines as an anti-cancer measure is overwhelming. However, vaccine uptake varies widely across countries and falls short of levels needed to achieve population immunity. We highlight policy measures that would help ensure greater worldwide coverage and save lives.
Source: Cell - Category: Cytology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer Vaccine | Cytology | Genital Warts | Human Papillomavirus (HPV) | Vaccines